This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BPMC Blueprint Medicines (BPMC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Blueprint Medicines Stock (NASDAQ:BPMC) Get Blueprint Medicines alerts:Sign Up Key Stats Today's Range$129.46▼$129.4650-Day Range$127.95▼$129.4852-Week Range$84.25▼$129.65VolumeN/AAverage Volume3.86 million shsMarket Capitalization$8.36 billionP/E RatioN/ADividend YieldN/APrice Target$129.00Consensus RatingHold Company Overview Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Read More Receive BPMC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BPMC Stock News HeadlinesShareholder Alert: The Ademi Firm Continues to Investigate the Blueprint Medicines Corporation TransactionSeptember 15, 2025 | businesswire.comShareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation TransactionAugust 27, 2025 | businesswire.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.June 8 at 1:00 AM | Behind the Markets (Ad)$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC)July 14, 2025 | globenewswire.comBPMC Blueprint Medicines Corporation - Seeking AlphaJuly 1, 2025 | seekingalpha.comBlueprint Medicines Corporation (BPMC) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comBlueprint Medicines Presents Strong Long-Term Data for AYVAKIT in Systemic MastocytosisJune 24, 2025 | msn.comBLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint ...June 22, 2025 | morningstar.comMSee More Headlines BPMC Stock Analysis - Frequently Asked Questions How were Blueprint Medicines' earnings last quarter? Blueprint Medicines Corporation (NASDAQ:BPMC) posted its earnings results on Thursday, May, 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.32. The business's revenue was up 55.5% compared to the same quarter last year. Read the conference call transcript. When did Blueprint Medicines IPO? Blueprint Medicines (BPMC) raised $130 million in an initial public offering on Thursday, April 30th 2015. The company issued 8,145,834 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What other stocks do shareholders of Blueprint Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Blueprint Medicines investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), Humana (HUM), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings5/01/2025Today6/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 BPMC's financial health is in the Green zone, according to TradeSmith. BPMC has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BPMC CIK1597264 Webwww.blueprintmedicines.com Phone(617) 374-7580FaxN/AEmployees640Year Founded2011Price Target and Rating Average Price Target for Blueprint Medicines$129.00 High Price Target$129.00 Low Price Target$129.00 Potential Upside/Downside-0.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$67.09 million Net Margins-27.70% Pretax Margin-27.38% Return on Equity-64.60% Return on Assets-17.22% Debt Debt-to-Equity Ratio1.01 Current Ratio2.80 Quick Ratio2.75 Sales & Book Value Annual Sales$562.12 million Price / Sales14.87 Cash FlowN/A Price / Cash FlowN/A Book Value$4.70 per share Price / Book27.54Miscellaneous Outstanding Shares64,582,000Free Float61,863,000Market Cap$8.36 billion OptionableOptionable Beta0.89 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:BPMC) was last updated on 6/8/2026 by MarketBeat.com Staff. From Our PartnersSpaceX billions need somewhere to go — this is itThe SpaceX IPO is projected to raise $75 billion in a single day... When that happens, the insiders who cashed...Crypto 101 Media | SponsoredAmerica's AI Future Needs a Domestic Fuel ChainAI dominance requires power at a scale most investors have not priced in - and nuclear energy is emerging as a...i2i Marketing Group, LLC | SponsoredTiny Nasdaq Firm Lands €13.9 Million Semiconductor DealOne small Nasdaq-listed company just landed a 13.9 million euro contract tied to a new advanced-node semicondu...Finplays | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour name isn't on our protected list yetI checked our download records for "The Big Beautiful Bubble Report" and didn't see your name. That concern...American Alternative | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredImportant SpaceX PREDICTIONThe biggest IPO in stock market history could go live as soon as June 12th — but trading legend Jon Najarian s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
